SCHEMBL2158798

SCHEMBL2158798

O=C(O)c1cc(Cl)nc2[nH]ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
USP2 O75604 1/20 0.40
HTT P42858 1/20 0.40
AURKA O14965 2/20 0.40
TPX2 Q9ULW0 2/20 0.40
F7 P08709 1/20 0.39
F3 P13726 1/20 0.39
PTGES O14684 1/20 0.38
ALDH1A1 P00352 1/20 0.38
ALOX5 P09917 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CASP7 P55210 1/20 0.38
HIF1A Q16665 1/20 0.38
HSD17B10 Q99714 1/20 0.38
KEAP1 Q14145 1/20 0.38
PTPRC P08575 1/20 0.37
PTPN2 P17706 1/20 0.37
PTPN1 P18031 1/20 0.37
PTPRB P23467 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10110217 0.85 NUDT1 (0.43) DYRK1ANUDT1
SCHEMBL2158555 0.83 KDM4E (0.58) KDM4EALDH1A1NUDT1MAPT
SCHEMBL31347077 0.83 KDM4E (0.58) KDM4EALDH1A1NUDT1MAPT
SCHEMBL23780720 0.78 NUDT1 (0.61) KDM4EALDH1A1HPGDNUDT1MEN1
SCHEMBL29442152 0.78 NUDT1 (0.61) KDM4EALDH1A1HPGDNUDT1MEN1
SCHEMBL3554174 0.76 ADORA2A (0.56) KDM4EF7F3HIF1AHSD17B10
SCHEMBL27939125 0.75 SLC22A6 (0.38) KDM4EHTTALDH1A1HPGDHSD17B10
SCHEMBL23329201 0.75 GAA (0.65) KDM4EHTTALDH1A1HPGDADORA2A
SCHEMBL13906236 0.74 PRKCI (0.52) DYRK1AADORA2AADORA1NUDT1CYP1A2
SCHEMBL31275227 0.74 PRKCI (0.52) DYRK1AADORA2AADORA1NUDT1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2313412-B1 NOVEL DERIVATIVES OF PYRROLOINDOLE INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF SANOFI SA (FR) 2013-01-02 EP claimed
CN-102124008-A Novel pyrroloindole derivatives as Hsp90 inhibitors, compositions containing said derivatives and uses thereof SANOFI AVENTIS 2011-07-13 CN claimed
CN-114174292-B Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors 修复治疗公司 2024-06-18 CN disclosed
US-20230025807-A1 CD38 INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2023-01-26 US disclosed
US-20230025807-A1 CD38 INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2023-01-26 US disclosed
CN-114174292-A Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors 修复治疗公司 2022-03-11 CN disclosed
CN-113454080-A Compounds, pharmaceutical compositions and methods of making compounds and methods of use thereof 修复治疗公司 2021-09-28 CN disclosed
WO-2021087087-A1 N-CYCLOHEXYL-5-(THIAZOL-5-YL)-1H-INDOLE-7-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS CD38 INHIBITORS FOR INCREASING NAD+ AND FOR THE TREATMENT OF E.G. MUSCULAR DISORDERS MITOBRIDGE INC. (US) 2021-05-06 WO disclosed
WO-2021087087-A1 N-CYCLOHEXYL-5-(THIAZOL-5-YL)-1H-INDOLE-7-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS CD38 INHIBITORS FOR INCREASING NAD+ AND FOR THE TREATMENT OF E.G. MUSCULAR DISORDERS MITOBRIDGE INC. (US) 2021-05-06 WO disclosed
US-8178687-B2 Derivatives of pyrroloindole which are inhibitors of Hsp90, compositions containing same, and use thereof SANOFI-AVENTIS (FR) 2012-05-15 US disclosed
US-20110184015-A1 NOVEL DERIVATIVES OF PYRROLOINDOLE WHICH ARE INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF SANOFI-AVENTIS (FR) 2011-07-28 US disclosed
CN-102124008-A Novel pyrroloindole derivatives as Hsp90 inhibitors, compositions containing said derivatives and uses thereof SANOFI AVENTIS 2011-07-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025807-A1 CD38 INHIBITORS CD38, GLS, IDH2 KDM4E 939/4885USP2 4492/4885HTT 1293/4885
US-20110184015-A1 NOVEL DERIVATIVES OF PYRROLOINDOLE WHICH ARE INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF HSP90AB1, HSP90AB2P, HSP90AA1 KDM4E 4551/4885USP2 1731/4885HTT 1076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.